Join us for a better future

Be the new Senior / Principal Scientist in an agile and innovative biotech company

Zealand Pharma A/S (Zealand) is seeking a Senior or Principal Scientist with significant in vivo and ex vivo experience within the gastro-intestinal field to join the Department of In vivo Pharmacology. The department is responsible for all non-clinical in vivo studies to support the R&D pipeline. We develop, characterise, and use animal models for evaluation of peptide drug candidates for the treatment of gastrointestinal and metabolic diseases. The department currently consists of four scientists, three laboratory technicians, four animal technicians, and one PhD student.

Job Profile

The successful candidate will:

 Evaluate, design and implement relevant in vivo and/or ex vivo gastro-intestinal disease models  Profile novel drug candidates in animal models in-house or at Contract Research Organizations (CROs) and interpret data  Initiate and evaluate new internal project proposals and evaluate external opportunities  Take part in or lead cross-departmental project teams to progress new drug candidates from preclinical discovery to early clinical development  Supervise laboratory technicians

Candidate Profile

The successful candidate will have:

 A PhD degree in pharmacology, physiology, biology, medicine, pathology, or related field  5-10 years of research experience with drug development in pharma/biotech  Significant experience with in vivo and ex vivo models within the field of gastro-intestinal diseases and translation to human disease  Experience with out-sourcing and monitoring CRO studies and collaborating with international academic groups  Capability to initiate scientific networks and drive scientific activities in the field of gastro-intestinal diseases  Interest in hands-on laboratory work  Experience with and/or interest in project management.  A positive attitude, self-motivated, and the ability to work independently and as team player

Zealand Pharma A/S 1/2

What we offer

Zealand’s employees are one of the company’s most important assets, and we strive to attract, develop and retain the best talents, and to be a company where employees thrive.

At Zealand, we understand the value of a diverse workforce, and as an employee you will be part of an innovative cross-disciplinary and cross-cultural working environment.

We offer a combined salary package including pension scheme and health insurance, as well as the option of joining the company lunch program, and use of massage, fitness and social facilities.

To find out more about working at Zealand, visit our careers site and view our company video at: www.zealandpharma.com/zealand-as-a-work-place/ www.zealandpharma.com/video-about-zealand-new/

Application About Zealand Pharma A/S

Please send your application Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology and CV no later than company focused on the discovery, design and development of innovative peptide- Thursday 21st September based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi, Boehringer Ingelheim and a pipeline of internal 2017: product candidates focusing on specialty gastrointestinal and metabolic diseases. [email protected] Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1 receptor agonist for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Adlyxin® in the U.S. and as Lyxumia® in the rest of the world. Lixisenatide or has been developed in a combination with basal insulin glargine (Lantus®) and is marketed as Soliqua® 100/33 in the U.S. and has been approved as Suliqua® in Zealand Pharma A/S Europe and launched in the Netherlands. Att.: Charlotte Madsen Smedeland 36 Zealand's clinical pipeline includes: dasiglucagon* (ZP4207, single-dose rescue DK-2600 Glostrup treatment) for acute, severe hypoglycemia (Phase 2); glepaglutide* (ZP1848) for short bowel syndrome (Phase 2); dasiglucagon* (ZP4207, multiple-dose version) intended for use in a dual-hormone artificial pancreas system to reduce the risk of hypoglycemia and better diabetes management (Phase 3) as well as for the treatment of congenital For further information, hyperinsulinism, and other earlier-stage clinical and preclinical peptide therapeutics. please contact Director, In vivo Pharmacology, Lene Zealand is based in Copenhagen (Glostrup), Denmark. For further information about Jessen the Company's business and activities, please visit www.zealandpharma.com or follow at +45 5060 3684 Zealand on Twitter @ZealandPharma. or [email protected] * Dasiglucagon and glepaglutide are proposed International Nonproprietary Names (pINN

Zealand Pharma A/S 2/2